The company now owns approximately 950,000 square feet of buildings in Rensselaer County, including warehouses, offices, manufacturing and research space. Regeneron Pharmaceuticals will spend ...

Regeneron is currently expanding its Tarrytown campus with an investment of nearly $3.6bn. ... a new fill/finish manufacturing facility is under construction in Rensselaer, New York, ...

Regeneron Pharmaceuticals could receive up to $140 million in incentives from New York State for its upstate expansion project. ALBANY, NY—Regeneron Pharmaceuticals Inc., which is headquartered ...

The Cuomo administration is offering drug maker Regeneron $140 million in incentives to expand its Rensselaer County operations over the next seven years, an effort that would include 1,500 new ...

Regeneron’s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing are expected to total more than $7 billion, the company stated, while also noting that ...

EAST GREENBUSH, N. Y. (WRGB) - Regeneron plans to create 1,500 new full-time jobs in the greater Capital Region. The plan comes as Regeneron is set to invest approximately $800 million over seven ...

New York state has offered Regeneron $140 million in incentives for the full build-out of the Tempel Lane campus, which is expected to cost Regeneron $800 million and would be home to 1,500 employees.

Regeneron Pharmaceuticals plans to add 1,000 jobs over the next five years at its Tarrytown, NY, headquarters, under a $1.8 billion expansion in which the company also plans to add to its research ...

Founded in 1988, Regeneron, the largest biotech company in New York, has called Westchester home for over 35 years as it has grown from four employees to about 11,800.

The drug maker picks a Rensselaer County site for its new manufacturing complex. ... Regeneron Pharmaceuticals is investing $800 million in East Greenbush, New York.

How a biotech company's high-priced, blockbuster drug spawns controversy—and eye-popping pay for executives (including one of the highest ranked on Crain's list of top-paid CEOs).